PUK16 EXPLORING THE IMPACT OF CHANGES IN NEUROGENIC URINARY INCONTINENCE FREQUENCY AND CONDITION SPECIFIC QUALITY OF LIFE ON PREFERENCE-BASED OUTCOMES  by Hollingworth, W et al.
health (PSH) proﬁle, were analyzed. RESULTS: A total of 131
patients were included in the waiting-list and 80% received a
kidney transplant, 41% were ECD. Sixty percent were men. The
age difference between ECD, SCD and not transplanted was
signiﬁcant (p = 0.000). The mean time in waiting-list (15 months)
and cold ischemia time (14 hours) were the same for both groups.
There were no differences in clinical variables. The PSH improve-
ment in ECD at year was signiﬁcant (p = 0.022), whereas for the
SCD not. There were differences in incomes (p = 0.041) between
groups. The survival at ﬁrst year was 100% for SCD and 97.7%
for ECD. At year, mean cost for SCD transplant was €54,343/year
versus €59.13€/year for ECD (no signiﬁcant). The difference in
QALYs between transplanted ones and not-transplanted was
signiﬁcant (p = 0.019). The utility was: 0.8096 QALYs for SCD,
0.7786 for ECD and 0.6838 for not transplanted. Cost-utility
analysis showed that one QALY in SCD cost €67.27€, versus
€79.95€/QALY of ECD and €80.43€/QALY of not transplanted in
waiting list. CONCLUSIONS: There were no clinical differences
and not in PSH at the ﬁrst transplant year between SCD and ECD,
but there were in age and what it bears. The differences in terms of
cost-utility, in the ﬁrst year, between ECD and not transplanted
were small. However, the differences could be important in long
term, because after the ﬁrst year the costs have an important
decrease. Therefore, it seems that ECD transplant have a good
results in health and costs.
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OBJECTIVES: To assess the cost and the resource use related to
anaemia management with Aranesp®, Eprex® and Neorecor-
mon(r) in patients with chronic renal failure treated with hae-
modialysis in Belgium; and to assess the effect of anaemia
management on haemoglobin (Hb) levels. METHODS: Data on
anaemia management and resource utilization were collected
using a retrospective chart review conducted in 11 haemodialysis
centres distributed across Belgium. From each centre between 30
and 40 patients were randomly selected. Data on drug use,
transfusion, consultations, hospitalizations, diagnostic tests and
Hb level were collected over a 1-year study period (1 December
2005 until 30 November 2006). The costs were calculated by
multiplying each item of resource use with its unit cost (in 2007;
in €) from the Belgian health care payer’s perspective (RIZIV/
INAMI). RESULTS: A total of 335 patients were included of
which 105, 132 and 98 were treated with Aranesp®, Eprex® and
Neorecormon(r), respectively. There were no demographic dif-
ferences between the treatment arms. There were no statistically
signiﬁcant differences between the 3 ESAs in the total annual
anaemia management cost in haemodialysis treated chronic renal
failure patients despite differences in drug list prices between the
3 ESAs. The cost ranged from €8203 to €9281. There were no
signiﬁcant differences in the average weekly dose of ESA between
the 3 drugs. Independent of the iron status of the patient, or
when stratiﬁed by CRP level, the percentage of patients reaching
a Hb level  11 g/dl was similar in the 3 treatment arms and
ranged from 76% to 81%. CONCLUSIONS: In patients with
chronic renal failure, treated with haemodialysis, there were no
signiﬁcant differences between the 3 available ESAs in medical
resource use, average dose of ESA needed, annual anaemia man-
agement costs from the perspective of the Belgian public health
care payer and in Hb control.
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OBJECTIVES: Due to their duration of action, current erythro-
poietin stimulating agents (ESA) require frequent administrations
(up to 3 injections per week). The objective of this study was a)
to estimate the potential time savings resulting from a switch to
a new once a month CERA (continuous erythropoietin receptor
activator), and b) to determine its beneﬁts in quality of care and
procedural improvements. METHODS: The different stages in
the global ESA Hospital Process (from ordering to invoicing)
were identiﬁed. A time and motion method was used for each
stage to determine the time spent managing ESA in eight dialysis
centres with different proﬁles. Simulations were performed to
assess the time savings according to various levels of the new
product’s penetration rates. Qualitative interviews with the
medical and administrative staff involved in the ESA manage-
ment were carried out to assess the expected beneﬁts of switching
to monthly injections. Intermediary and ﬁnal results were vali-
dated by a Scientiﬁc Committee. RESULTS: Current ESA man-
agement requires between 6 h 12 min and 20 h 36 min per
patient per year. The estimated total time saved by switching
to monthly injections ranged from 5 h 13 min to 17 h 29 min per
patient per year. Pharmacists and nurses are the two staff catego-
ries most affected by the time savings, which are respectively
from 28 min to 13 h and from 51 min to 3 h 32 m per patient
per year. Qualitative interviews supported these results and also
highlighted a potential time savings for administrative staff.
CONCLUSIONS: Administration of a monthly CERA injection
could reduce total time spent on ESA management by up to 85%
(for a total conversion). Time saved would allow the staff
involved to improve both their organisation and procedures
(stock management, outdated products, etc.) and their quality of
care (optimisation for Continuing Professional Development
indicators: patient close monitoring, compliance, etc.).
URINARY/KIDNEY DISORDERS—
Patient-Reported Outcomes Studies
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OBJECTIVES: Many trials do not measure Quality Adjusted Life
Years (QALYs). Therefore decision analysts wishing to extrapo-
late trial results for policy makers often map condition speciﬁc
outcomes to preference scores. We estimated the relationship
between changes in preference scores and commonly reported
condition speciﬁc outcomes in patients with neurogenic urinary
incontinence (UI). METHODS: In 59 patients recruited to a
neurogenic UI randomised controlled trial, clinical outcomes (UI
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episodes), condition speciﬁc quality of life (Incontinence Quality
of Life Questionnaire (I-QOL)), and SF-6D preference scores were
measured at enrollment and 24weeks after treatmentwith a single
injection of botulinum toxin type A or placebo. We measured the
correlation between SF-6D, I-QOL and UI episode change scores.
We used multiple linear regressions to estimate the impact on
SF-6D scores of 50%; 50%–99% and 100% reductions in UI
episodes and a 10-point improvement in I-QOL. These thresholds
are thought to be clinically signiﬁcant and are often reported as
trial outcomes. RESULTS: SF-6D change scores between enroll-
ment and 24 weeks were moderately correlated with I-QOL
change scores (rho = 0.41; p < 0.01) but non-signiﬁcantly corre-
lated with UI episode changes scores (rho = -0.19; p = 0.20). At
24weeks, mean (95%CI) daily UI episodes fell by 0.85 (0.04, 1.3)
and mean I-QOL scores improved by 18 (12, 24). SF-6D scores
increased by 0.03 (0.003, 0.058), due, primarily, to improvements
in the role limitations domains. A50% reduction in UI episodes
was achieved by 49% of patients and corresponded to a 0.09
(0.02, 0.16) SF-6D increase. A  10-point increase in I-QOL was
attained by 65% of patients and was associated with a 0.05
(-0.02, 0.12) SF-6D increase. CONCLUSIONS: These estimates
provide preliminary data for decision analysts wishing to map UI
outcomes to preference scores. The results demonstrate that clini-
cally important changes in condition speciﬁc quality of life are
reﬂected in SF-6D preference scores.
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OBJECTIVES: A randomized clinical trial (TIMES) demon-
strated that combination therapy with tolterodine extended
release (ER) plus tamsulosin for 12 weeks provides clinical ben-
eﬁts over monotherapy with either agent or placebo in men with
moderate to severe lower urinary tract symptoms (LUTS) and
overactive bladder. However, the TIMES study did not report
the impact of these therapies on utility. We developed a statisti-
cal model to predict the utility and quality-adjusted life-years
(QALYs) associated with the various TIMES therapies.
METHODS: The statistical model was developed using urinary
tract symptoms and quality of life (SF-12) data collected from
9416 males participating as part of a separate epidemiologic
survey (EpiLUTS). The model was a multinomial regression,
which predicted the level of responses to each of the 12 domains
of the SF-12. The predictors were daytime and nighttime urinary
frequency, urgency episodes, urge incontinence and International
Prostate Symptom Scores (IPSS). This regression was then used
to predict SF-12 scores of the TIMES patients, based on the
observed mean symptoms values in this study. Next, based on
published regression algorithms, these predicted SF-12 answers
were transformed into EQ-5D utility scores, from which QALYs
were calculated. RESULTS: IPSS score and number of urgency
episodes in 24 hours had the strongest impact on overall utility,
whereas nighttime and especially daytime micturition frequency
had less impact. At week 12, utility scores for placebo, toltero-
dine monotherapy, tamsulosin monotherapy, and combination
therapy were 0.657, 0.684, 0.679 and 0.701, respectively. Cor-
responding QALYs over 12 weeks were 0.143, 0.146, 0.146 and
0.148. Thus, combination therapy resulted in the highest incre-
mental QALYs, saving 0.005 QALYs vs. placebo, 0.002 vs.
tolterodine, and 0.003 vs. tamsulosin. CONCLUSIONS: Com-
bination therapy with tolterodine ER plus tamsulosin results in
the highest predicted utility and QALY gains compared to
placebo or monotherapy with either agent.
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OBJECTIVES: To assess the validity of the Urinary Sensation
Scale (USS) in women with overactive bladder (OAB) and men
with OAB and prostate symptoms (OAB-BPH). METHODS:
Data from 2 clinical trials of tolterodine treatment for OAB were
used to assess the validity of the USS, a 5-point rating scale to
assess the amount of urinary urgency associated with each uri-
nation. The USS ranges from “No feeling of urgency: I could
continue activities until I chose to use the bathroom” to “Unable
to hold; leak urine: I had a wetting accident before arriving at the
bathroom.” The USS was administered with a daily bladder diary
in the 2 trials. Two methods to evaluate the USS are to calculate
a mean urgency score (Mean USS) of all voids or to sum all
urgency ratings (Sum USS). Concurrent validity, discriminant
validity, and responsiveness of the USS were assessed. RESULTS:
Data from 580 men (Trial 1) and 331 women (Trial 2) were
analyzed. Mean age was 65.2 (men) and 47.8 (women); in both
studies, 70% were Caucasian. Correlations of USS scores with
bladder diary variables were small to moderate and higher
among Sum USS than Mean USS. Correlations among the USS
with OAB-q, Perception of Bladder Condition (PBC), and Per-
ception of Treatment Beneﬁt (PTB) were moderate to strong and
higher with Sum USS. Both the Mean and Sum USS signiﬁcantly
discriminated (all p < 0.001) among all bladder diary variables
(except men, nocturia and UUI) when grouped as improved/not
improved as well as by the OAB-q, PBC, and PTB. Effect sizes for
men and women respectively were -0.52 and -1.09 for Mean
USS and -0.72 and -1.36 for Sum USS. CONCLUSIONS: The
USS is a valid and highly responsive measure of urinary urgency
in women with OAB and men with OAB-BPH.
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OBJECTIVES: To evaluate the psychometric properties of 10
language versions of the King’s Health Questionnaire (KHQ).
METHODS: The KHQ, a 21-item instrument to assess health-
related quality of life in patients with urinary incontinence and
OAB, has been translated into numerous languages. Data from
a multicenter, randomized, double-blind, placebo- and active-
controlled trial of fesoterodine for OAB patients were analyzed to
assess the psychometric properties of the KHQ in ten languages.
Patients completed the KHQ at Baseline (BL) and Week 12 of
treatment and bladder diaries for 3 days before each visit. Mean
BL scores, Cronbach alphas, and subscale change scores were
calculated for the KHQ in each language. RESULTS: Data from
839 patients were analyzed (Australia = 104; Bulgaria = 58;
Czech Republic = 55; Estonia = 59; Germany = 59; New Zealand
(NZ) = 82; Poland = 84; Romania = 66; Russia = 81; and South
Africa = 191). Mean age was 56.7  13.9 years; 80% were
female; 96% were white. BL subscale scores ranged from 16.8
(General Health Perceptions [GHP]; NZ English) to 83.6 (Impact
on Life; German). Six of 7 multi-item KHQ subscales (Role
Abstracts A655
